-
ALSO READ
SPARC board to mull fund raising on 1 Sept
Board of Sparc Systems approves change in CFO and appointment of director
SPARC adds over 8% in two days
Five drug makers collaborate for clinical trial of Molnupiravir
Sparc Systems reports standalone net loss of Rs 1.94 crore in the March 2021 quarter
-
On a standalone basis, Sun Pharma Advanced Research Company (SPARC)'s net loss during Q2 FY22 stood at Rs 55.14 crore as comperd to a net loss of Rs 61.37 crore in Q2 FY21.
Standalone revenue from operations surged 57.99% to Rs 27.87 crore in Q2 September 2021 as against Rs 17.64 crore in Q2 September 2020.
Shares of Sun Pharma Advanced Research Company (SPARC) gained 1.12% to Rs 269.90 on BSE. SPARC is a clinical stage bio-pharmaceutical company, It was formed in 2007 through a demerger from Sun Pharma, a global leader in speciality generics.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU